Skip to content

Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)

Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03622333
Enrollment
60
Registered
2018-08-09
Start date
2018-05-28
Completion date
2022-11-28
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Intestinal Carcinoid Tumors

Keywords

Neuroendocrine tumors, carcinoid tumors, midgut, small intestine, genetic predisposition, hereditary

Brief summary

Small intestine carcinoid tumors are rare. Small intestine Familial Carcinoid Tumors (FCT) are defined by the occurrence of at least 2 cases of this tumor type in first- or second-degree relatives. The estimated prevalence of FCT is 2.6%-3.7% in patients with small intestine carcinoid tumors. Because of its rarity, epidemiologic, clinic and pathologic features of FCT have been scarcely described. Molecular abnormalities associated with FCT have been poorly explored. Constitutional genetic factors predisposing to FCT have not been discovered to date. Only one abnormality (mutation of the IPMK gene) has been reported in one FCT family only, but not found in other series. The main objective of this study is to identify the constitutional factors predisposing to small-intestine FCT (and other midgut localizations: ascending colon and appendix). The secondary objectives are to describe the clinic and pathologic features associated with FCT.

Interventions

GENETICResearch of constitutional genetic alterations

Tumor DNA extraction Blood sample and constitutional DNA extraction CGH-array, Exome sequencing Bio-informatic analysis

Sponsors

CHU de Reims
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

: * Small-intestine (or ascending colon or appendix) neuroendocrine tumor (proven histologically) * At least one first- or second-degree relative with a small-intestine (or ascending colon or appendix) neuroendocrine tumor (proven histologically) * Agreement to participate to the study

Exclusion criteria

: * Subjects unable to provide consent

Design outcomes

Primary

MeasureTime frameDescription
Deletionday 0Quantitative Constitutional genetic alterations detected by comparative genomic hybridization (CGH array)
duplicationDay 0Quantitative Constitutional genetic alterations detected by comparative genomic hybridization (CGH array)
amplificationDay 0Quantitative Constitutional genetic alterations detected by comparative genomic hybridization (CGH array)
mutationDay 0qualitative Constitutional genetic alterations detected by NGS (Next Generation Sequencing)

Countries

France

Contacts

Primary ContactGuillaume CADIOT
gcadiot@chu-reims.fr03 26 78 84 41
Backup ContactLouis DE MESTIER
louis.demestier@aphp.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026